CN109480132A - 一种含壳寡糖的液体健康饮料及其制备方法和应用 - Google Patents
一种含壳寡糖的液体健康饮料及其制备方法和应用 Download PDFInfo
- Publication number
- CN109480132A CN109480132A CN201811325019.8A CN201811325019A CN109480132A CN 109480132 A CN109480132 A CN 109480132A CN 201811325019 A CN201811325019 A CN 201811325019A CN 109480132 A CN109480132 A CN 109480132A
- Authority
- CN
- China
- Prior art keywords
- chitosan oligosaccharide
- parts
- beverage
- liquid
- mulberry
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000013361 beverage Nutrition 0.000 title claims abstract description 70
- RQFQJYYMBWVMQG-IXDPLRRUSA-N chitotriose Chemical compound O[C@@H]1[C@@H](N)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](N)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)[C@@H](CO)O1 RQFQJYYMBWVMQG-IXDPLRRUSA-N 0.000 title claims abstract description 70
- 239000007788 liquid Substances 0.000 title claims abstract description 41
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims abstract description 42
- 239000000284 extract Substances 0.000 claims abstract description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 24
- 235000020717 hawthorn extract Nutrition 0.000 claims abstract description 22
- 235000013373 food additive Nutrition 0.000 claims abstract description 16
- 239000002778 food additive Substances 0.000 claims abstract description 16
- 239000001509 sodium citrate Substances 0.000 claims abstract description 14
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims abstract description 14
- 235000019202 steviosides Nutrition 0.000 claims abstract description 14
- 239000004383 Steviol glycoside Substances 0.000 claims abstract description 13
- 239000008103 glucose Substances 0.000 claims abstract description 13
- 229930182488 steviol glycoside Natural products 0.000 claims abstract description 13
- 235000019411 steviol glycoside Nutrition 0.000 claims abstract description 13
- 150000008144 steviol glycosides Chemical class 0.000 claims abstract description 13
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 8
- 238000006116 polymerization reaction Methods 0.000 claims abstract description 6
- 235000015165 citric acid Nutrition 0.000 claims abstract description 4
- 230000036541 health Effects 0.000 claims abstract description 4
- 235000011083 sodium citrates Nutrition 0.000 claims abstract description 4
- 239000000203 mixture Substances 0.000 claims description 29
- 241000894006 Bacteria Species 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 13
- 230000009286 beneficial effect Effects 0.000 claims description 12
- 239000002994 raw material Substances 0.000 claims description 8
- 238000009928 pasteurization Methods 0.000 claims description 7
- 239000007787 solid Substances 0.000 claims description 7
- 240000000249 Morus alba Species 0.000 claims description 5
- 235000008708 Morus alba Nutrition 0.000 claims description 5
- 230000002335 preservative effect Effects 0.000 claims description 5
- JXKPEJDQGNYQSM-UHFFFAOYSA-M sodium propionate Chemical compound [Na+].CCC([O-])=O JXKPEJDQGNYQSM-UHFFFAOYSA-M 0.000 claims description 5
- 235000010334 sodium propionate Nutrition 0.000 claims description 5
- 239000004324 sodium propionate Substances 0.000 claims description 5
- 229960003212 sodium propionate Drugs 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- 208000017170 Lipid metabolism disease Diseases 0.000 claims description 4
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 claims description 4
- 229940107187 fructooligosaccharide Drugs 0.000 claims description 4
- 239000003755 preservative agent Substances 0.000 claims description 4
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 claims description 3
- 235000021028 berry Nutrition 0.000 claims description 3
- 235000013402 health food Nutrition 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 3
- 235000010241 potassium sorbate Nutrition 0.000 claims description 3
- 239000004302 potassium sorbate Substances 0.000 claims description 3
- 229940069338 potassium sorbate Drugs 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 244000182067 Fraxinus ornus Species 0.000 claims description 2
- 235000002917 Fraxinus ornus Nutrition 0.000 claims description 2
- 229920002752 Konjac Polymers 0.000 claims description 2
- 235000013312 flour Nutrition 0.000 claims description 2
- 239000002023 wood Substances 0.000 claims description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims 2
- 239000005711 Benzoic acid Substances 0.000 claims 1
- 235000007516 Chrysanthemum Nutrition 0.000 claims 1
- 244000189548 Chrysanthemum x morifolium Species 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 235000010233 benzoic acid Nutrition 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 229940083542 sodium Drugs 0.000 claims 1
- 235000015424 sodium Nutrition 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 33
- 230000000968 intestinal effect Effects 0.000 abstract description 18
- 239000008280 blood Substances 0.000 abstract description 11
- 210000004369 blood Anatomy 0.000 abstract description 11
- 230000006872 improvement Effects 0.000 abstract description 7
- 230000000694 effects Effects 0.000 abstract description 6
- 150000002632 lipids Chemical class 0.000 abstract description 6
- 230000001603 reducing effect Effects 0.000 abstract description 5
- 230000035622 drinking Effects 0.000 abstract description 4
- 230000004060 metabolic process Effects 0.000 abstract description 4
- 238000012545 processing Methods 0.000 abstract description 3
- 230000002195 synergetic effect Effects 0.000 abstract description 3
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 abstract description 2
- 229930186217 Glycolipid Natural products 0.000 abstract description 2
- 239000002075 main ingredient Substances 0.000 abstract description 2
- 208000002705 Glucose Intolerance Diseases 0.000 abstract 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 abstract 1
- 239000012530 fluid Substances 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- 230000000052 comparative effect Effects 0.000 description 18
- 230000006870 function Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 6
- 108010007622 LDL Lipoproteins Proteins 0.000 description 5
- 102000007330 LDL Lipoproteins Human genes 0.000 description 5
- 229910052500 inorganic mineral Inorganic materials 0.000 description 5
- 239000011707 mineral Substances 0.000 description 5
- 238000012856 packing Methods 0.000 description 5
- 241000186000 Bifidobacterium Species 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 150000003626 triacylglycerols Chemical class 0.000 description 4
- 241000605716 Desulfovibrio Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 229920001202 Inulin Polymers 0.000 description 3
- 208000008589 Obesity Diseases 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 3
- 229940029339 inulin Drugs 0.000 description 3
- 208000030159 metabolic disease Diseases 0.000 description 3
- 235000020824 obesity Nutrition 0.000 description 3
- 235000013406 prebiotics Nutrition 0.000 description 3
- 239000006041 probiotic Substances 0.000 description 3
- 235000018291 probiotics Nutrition 0.000 description 3
- 230000000770 proinflammatory effect Effects 0.000 description 3
- 241000702460 Akkermansia Species 0.000 description 2
- 229920001503 Glucan Polymers 0.000 description 2
- 241000589516 Pseudomonas Species 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- TWNIBLMWSKIRAT-VFUOTHLCSA-N levoglucosan Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@H]2CO[C@@H]1O2 TWNIBLMWSKIRAT-VFUOTHLCSA-N 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 210000000697 sensory organ Anatomy 0.000 description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 2
- 235000010234 sodium benzoate Nutrition 0.000 description 2
- 239000004299 sodium benzoate Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- 241000238421 Arthropoda Species 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- -1 Chitosan oligosaccharide compound Chemical class 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 241001092040 Crataegus Species 0.000 description 1
- 235000009917 Crataegus X brevipes Nutrition 0.000 description 1
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 description 1
- 235000009685 Crataegus X maligna Nutrition 0.000 description 1
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 description 1
- 235000009486 Crataegus bullatus Nutrition 0.000 description 1
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 description 1
- 235000009682 Crataegus limnophila Nutrition 0.000 description 1
- 235000004423 Crataegus monogyna Nutrition 0.000 description 1
- 235000002313 Crataegus paludosa Nutrition 0.000 description 1
- 235000009840 Crataegus x incaedua Nutrition 0.000 description 1
- 241000605909 Fusobacterium Species 0.000 description 1
- 241000589989 Helicobacter Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 244000302512 Momordica charantia Species 0.000 description 1
- 235000009811 Momordica charantia Nutrition 0.000 description 1
- 235000009812 Momordica cochinchinensis Nutrition 0.000 description 1
- 235000018365 Momordica dioica Nutrition 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 1
- 241000863032 Trieres Species 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000011217 control strategy Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000005452 food preservative Substances 0.000 description 1
- 235000019249 food preservative Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000003345 hyperglycaemic effect Effects 0.000 description 1
- 230000003516 hyperlipidaemic effect Effects 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000013370 mutualism Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 229940013618 stevioside Drugs 0.000 description 1
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 1
- 235000012976 tarts Nutrition 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 229920001221 xylan Polymers 0.000 description 1
- 150000004823 xylans Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/02—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation containing fruit or vegetable juices
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7016—Disaccharides, e.g. lactose, lactulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/722—Chitin, chitosan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/733—Fructosans, e.g. inulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
本发明公开了一种含壳寡糖的液体健康饮料及其制备方法和应用,具体涉及饮料及食品加工行业。本发明液体饮料所含主要成份:水、壳寡糖、山楂提取物、桑叶提取物、甜菊糖苷、柠檬酸、柠檬酸钠、食品添加剂。本发明中的壳寡糖聚合度为2‑20,分子量范围为200‑5000Da。本发明饮料中特定比例的壳寡糖和山楂提取物及桑叶提取物在调节肠道菌群作用、降低血脂、降低血糖、改善糖尿病或糖脂代谢综合征疾病方面具有协同增效作用。本发明饮料适用于血糖高、血脂高、葡萄糖不耐受的患者,可满足其日常饮用及健康需求。
Description
技术领域
本发明涉及食品饮料加工技术领域,具体地,本发明提供了一种含壳寡糖的液体健康饮料及其制备方法和应用。
背景技术
肠道菌群是寄生在宿主肠道内的细菌群落的总称,肠道中丰富的营养物质滋养了数量庞大肠道细菌群落,有研究证明其数量超过宿主细胞的10倍,其中大部分位于大肠部位。在正常情况下,肠道细菌与宿主之间存在互惠互利、互利共生的状态。肠道菌群的组成和多样性是宿主基因背景、饮食习惯、作息规律、健康状态的重要反映。近10年的大量研究表明,肠道细菌参与肥胖、炎性肠病、肿瘤癌化、糖尿病、神经退行性疾病的调节过程。肠道细菌可以通过自身组成部分或其代谢组分等影响宿主肠道代谢、免疫、激素和神经感应等重要环节。越来越多的证据表明靶向肠道细菌的调控方式或将成为防治代谢性疾病及慢性炎症疾病重要的防治策略。肠道菌群的组成复杂而易变,只有采用相对精准的调控手段才能使得肠道细菌中有益部分得到放大而不引入未知的致病因素。现阶段最经济有效的特异性菌群调控手段是采用益生元或类似益生元的成份,通过饮食的方式进入肠道而调节细菌的组成和丰富度。因此,目前针对肠道微生物进行调控的功能食品开发前景广阔、市场需求巨大。
壳寡糖是从节肢动物外骨骼的主要成份(甲壳素、壳聚糖)中降解、提取、分离、纯化而成的以氨基葡萄糖为单元通过β1-4糖苷键连接聚合度2-20的寡聚物。大量的科学研究表明,带正电荷、可溶性好的壳寡糖具有丰富的功能调节活性:抗氧化、抗炎、抗肿瘤、调节免疫、降血糖、降血脂、抑菌、调节肠道菌群的功能。但现有的技术专利极少研究壳寡糖在调节肠道菌群方面的应用。
中国专利CN 105595308 A本发明涉及一种具有辅助降血糖功能的壳寡糖复合粉,由以下组分按重量分数组成:燕麦β-葡聚糖40-60份,壳寡糖5-20份,黄精提取物5-20份,桑叶提取物3-8份,苦瓜提取物2-6份,富铬酵母0.05-0.5份,填充剂10-20份。该发明以壳寡糖和燕麦β-葡聚糖为主要功效成分辅以多种传统中药活性成分相配伍,采用超声乳化、喷雾干燥技术精制而得的壳寡糖复合物,具有溶解性好、分散性好、吸收利用度高的优势,该发明各种组分相互协同,起到促进血糖代谢、养护调节胰岛机能作用,但是该专利中并没有说明该壳寡糖复合粉具有调节肠道菌群的用途。并且该专利配方较复杂,成本较高,其中采用苦瓜等提取物对口感有很大影响。
中国专利CN 108514563 A本发明公开了壳寡糖用于动物肠道菌群紊乱的调节剂应用、壳寡糖、含有壳寡糖的混合物以及相应的用途。该发明的壳寡糖聚合度为2-20,可以调节肥胖或糖尿病或饮食结构不合理引起的肠道菌群紊乱,促进肠道Akkermansia、Bifidobacterium、Lactobacillus等有益菌的生长,显著抑制Desulfovibrio、Helicobacter等有害菌的增殖。该发明提供了将所述壳寡糖单独或与益生菌形成组合物按照常规工艺制成临床上接受的药物制剂或保健食品,具有调节小鼠肠道菌群紊乱的作用,但是该专利中仅仅对小鼠肠道菌群的改善周期较长,单独采用壳寡糖或壳寡糖与益生菌组合物,改善周期分别长达5个月和2个月。用于人体时,如果服用时间需要超过2个月才有改善效果,增加了使用成本,也必然会给使用者带来较多不变,当使用前期没有明显改善效果时,容易让人对产品失去信心而停用。另外如果长期服用益生菌可能会使人体对其产生依赖,会使肠道自身调节功能减弱。
发明内容
针对以上技术的不足,本发明旨在克服现有技术不足,提供一种含壳寡糖的液体健康饮料,采用壳寡糖、山楂及桑叶为基本原料,具有较好的口感,可在较短时间内快速调节肠道菌群紊乱,并且可以显著改善高血糖、高血脂患者的病症。
本发明的一种含壳寡糖的液体健康饮料,由以下质量份数的原料和水混合配制而成:壳寡糖40-80份、山楂提取物20-50份、桑叶提取物8-20份、甜菊糖苷8-20份、柠檬酸5-20份、柠檬酸钠2-20份、食品添加剂0.01-0.1份;所述壳寡糖在液体健康饮料中的最终浓度为0.1-10mg/mL。
优选地,所述含壳寡糖的液体健康饮料由以下质量份数的原料和水混合配制而成:壳寡糖50-70份、山楂提取物30-50份、桑叶提取物8-18份、甜菊糖苷8-16份、柠檬酸6-15份、柠檬酸钠3-10份、食品添加剂0.02-0.08份;所述壳寡糖在液体健康饮料中的最终浓度为0.2-5mg/mL。
优选地,所述山楂提取物的浓度为10%-30%,是山楂果经常规水提方法得到的组分。
优选地,所述桑叶提取物浓度为5%,是桑叶经常规水提方法得到的组分。
优选地,所述壳寡糖聚合度为2-20之间,分子量200-5000Da。
优选地,所述食品添加剂包括益菌物质、防腐剂。
优选地,所述食品添加剂中的益菌物质和防腐剂的质量比例为0.1-99.9。
优选地,所述益菌物质为菊粉、魔芋粉、果寡糖、木寡糖、甘露寡糖中的至少一种。
优选地,所述防腐剂为苯甲酸钠、山梨酸钾、丙酸钠中的至少一种。
本发明的含壳寡糖的液体健康饮料的制备方法,包括以下步骤:
(1)将壳寡糖、甜菊糖苷、柠檬酸、柠檬酸钠、食品添加剂等固体按比例加入水中,混匀;
(2)再将桑叶提取物和山楂提取物加入步骤(1)所得的混合物中,混匀。
(3)采用巴氏消毒法,将步骤(2)所得混合物在70℃条件下灭菌30min,然后按体积分装后迅速降低至4℃,并冷藏保存。
本发明的含壳寡糖的液体健康饮料可以应用在调节肠道菌群紊乱或/和糖脂代谢紊乱疾病的保健食品和药物制剂中。
本发明的液体饮料配方简单,其中壳寡糖具有菌群调节功效;桑叶提取物具有改善糖尿病的效果;利用山楂提取物、甜菊苷、柠檬酸、柠檬酸钠可以调和饮用口感,并提高壳寡糖在水溶液中的稳定性;并且特定比例的桑叶提取物、山楂提取物与壳寡糖具有协同作用,可显著快速地调控人体肠道菌群、改善糖脂代谢紊乱;菊粉、果寡糖等益生元进一步提高本饮料对肠道菌群的调控能力。
与现有技术相比,本发明的含壳寡糖的液体健康饮料的有益效果为:本发明的液体饮料在保证慢性代谢疾病患者对健康的要求前提下,满足消费者的口味需求。不仅可以预防和治疗糖脂代谢紊乱的相关疾病,如肥胖、非酒精性脂肪肝、高血脂症、糖尿病等,而且可在较短时间内改善肠道菌群紊乱。本发明技术方案简单,配方和制备工艺简单,成本低、易于工业化量产,具有较好的市场前景,是慢性代谢疾病或亚健康人群适宜的药食两用饮品。
附图说明
附图为不同液体饮料对糖尿病个体肠道菌群的改善情况。
图1为肠道菌群多样性chao1指数;
图2为肠道菌群多样性PD whole tree指数;
图3为有益菌双歧杆菌属变化;
图4为有益菌Akkermansia菌属变化;
图5为促炎菌脱硫弧菌属变化;
图6为条件致病菌梭菌属变化
其中:正常组指正常个体饮用矿泉水,糖尿病组指糖尿病个体饮用矿泉水,糖尿病1#组指糖尿病个体饮用对比例1所得饮料,糖尿病2#组指糖尿病个体饮用对比例2所得饮料,糖尿病3#组指糖尿病个体饮用实施例3所得饮料。“*”代表糖尿病组与正常组相比有显著差异,“#”或“##”代表糖尿病处理组与糖尿病组相比有显著差异。
具体实施方式
本发明实施例的含壳寡糖的液体健康饮料,一种含壳寡糖的液体健康饮料,由以下质量份数的原料和水混合配制而成:壳寡糖40-80份、山楂提取物20-50份、桑叶提取物8-20份、甜菊糖苷8-20份、柠檬酸5-20份、柠檬酸钠2-20份、食品添加剂0.01-0.1份;所述壳寡糖在液体健康饮料中的最终浓度为0.1-10mg/mL。
所述壳寡糖聚合度为2-20之间,分子量200-5000Da。
所述桑叶提取物浓度为5%,是桑叶经常规水提方法得到的组分。
所述山楂提取物的浓度为20%,是山楂果经常规水提方法得到的组分。
实验发现当上述桑叶提取物、山楂提取物与壳寡糖的配比为1:4~5:8~10时,三种原料的协同作用更好,可以更快更显著地改善肠道菌群和糖脂代谢紊乱。
以下结合实施例对本发明各技术方案进行清楚、完整的描述,显然,所描述的实施例仅仅是本发明的一部分实施例,而不是全部的实施例。基于本发明的实施例,本领域普通技术人员在没有做出创造性劳动的前提下所得到的所有其它实施例,都属于本发明所保护的范围。本领域技术人员依据以下实施方式所作的方法、工艺路线、功能的等效变换或替代,均属于本发明的保护范围之内。
实施例1
在本实施例中,提供了一种含壳寡糖的液体健康饮料及其制备方法,具体实施步骤如下:
(1)将50g壳寡糖、10g甜菊糖苷、6g柠檬酸、3g柠檬酸钠、0.02g食品添加剂(0.01g菊粉,0.02g苯甲酸钠)等固体加入50L水中,混匀;
(2)再将10g桑叶提取物(5%)和50g山楂提取物(20%)加入步骤(1)所得的混合物中,混匀。
(3)采用巴氏消毒法,将步骤(2)所得混合物在70℃条件下灭菌30min,200mL分装成小袋,4℃低温冷藏。
实施例2
在本实施例中,提供了一种含壳寡糖的液体健康饮料制备方法,具体实施步骤如下:
(1)将60g壳寡糖、12g甜菊糖苷、8g柠檬酸、4g柠檬酸钠、0.03g食品添加剂(0.02g果寡糖,0.01g山梨酸钾)等固体加入50L水中,混匀;
(2)再将16g桑叶提取物(5%)和30g山楂提取物(20%)加入步骤(1)所得的混合物中,混匀。
(3)采用巴氏消毒法,将步骤(2)所得混合物在70℃条件下灭菌30min,按360mL分装成小瓶,4℃低温冷藏。
实施例3
在本实施例中,提供了一种含壳寡糖的液体健康饮料制备方法,具体实施步骤如下:
(1)将70g壳寡糖、14g甜菊糖苷、8g柠檬酸、4g柠檬酸钠、0.04g食品添加剂(0.02g低聚木糖,0.02g丙酸钠)等固体加入50L水中,混匀;
(2)再将8g桑叶提取物(5%)和40g山楂提取物(30%)加入步骤(1)所得的混合物中,混匀。
(3)采用巴氏消毒法,将步骤(2)所得混合物在70℃条件下灭菌30min,360mL分装成小瓶,4℃低温冷藏。
对比例1
在本对比例提供了一种含壳寡糖的液体健康饮料制备方法,具体实施步骤如下:
(4)将110g壳寡糖、14g甜菊糖苷、8g柠檬酸、4g柠檬酸钠、0.04g食品添加剂(0.02g低聚木糖,0.02g丙酸钠)等固体加入50L水中,混匀;
(5)再将8g桑叶提取物(5%)加入步骤(1)所得的混合物中,混匀。
(6)采用巴氏消毒法,将步骤(2)所得混合物在70℃条件下灭菌30min,360mL分装成小瓶,4℃低温冷藏。
即相比实施例3,本对比例的液体中不含有山楂提取物,而增加了40g壳寡糖,其它与实施例1相同。
对比例2
在本实施例中,提供了一种含壳寡糖的液体健康饮料制备方法,具体实施步骤如下:
(7)将8g壳寡糖、14g甜菊糖苷、8g柠檬酸、4g柠檬酸钠、0.04g食品添加剂(0.02g低聚木糖,0.02g丙酸钠)等固体加入50L水中,混匀;
(8)再将8g桑叶提取物(5%)和102g山楂提取物(30%)加入步骤(1)所得的混合物中,混匀。
(9)采用巴氏消毒法,将步骤(2)所得混合物在70℃条件下灭菌30min,360mL分装成小瓶,4℃低温冷藏。
即相比实施例3,本对比例中改变桑叶提取物、山楂提取物与壳寡糖的配比为1:12.75:1,三种原料的添加总量不变,其它与实施例3相同。
应用例1
饮用口感测试
将实施例1-3所获得的液体健康饮料,完成以下测试:
请10位正常人和10位糖尿病患者品尝3种不同饮料,请试用者对饮料进行感官评定,评定标准见表1。评定的分值记录到表2。
表1.饮料的感官评价标准
结果:表2显示,实施例1-3的饮料的甜度、口感和气味都被受试者普遍接受,同时该饮料特有的酸味也处于均能接受的水平,其中3#饮料(实施例3所得饮料)呈现的口感和风味均较好。
表2.饮料的感官评打分
应用例2
功效测试
将实施例3和对比例1-2所获得的液体健康饮料,完成以下测试:
(1)请10位健康人为一组,40位糖尿病患者随机分成4组,每组十人。实验总共5组,每组10人,分别为糖尿病1#饮料组(糖尿病患者喝对比例1饮料),糖尿病2#饮料组(糖尿病患者喝对比例2饮料),糖尿病3#饮料组(糖尿病患者喝实施例3饮料),正常组(正常人饮用同等体积的矿泉水),糖尿病组(糖尿病患者饮用同等体积的矿泉水),实验开始前,检测受试者的空腹血糖,血脂体重等指标。
(2)试验开始时,每组糖尿病患者分别服用对应液体饮料,每日1瓶(500ml),未加饮料组仅饮用同等体积的矿泉水,试验为期1个月。分别在实验2周时,检测受试者的生理指标、血糖、血脂等变化,实验1个月结束时再次检测受试者的生理指标、血糖、血脂以及肠道菌群等变化,详细结果见表3和图1。
表3结果提示,3种功能液体饮料在实验进行1个月时均可一定程度改善糖尿病患者的空腹高血糖,其中实施例3的饮料对空腹血糖的降低效果最为显著,且可以同时显著的降低甘油三酯和低密度脂蛋白含量,而对比例1和对比例2的饮料对甘油三酯和低密度脂蛋白含量的降低效果不显著。
在实验进行两周时,对比例1和对比例2的饮料对糖尿病患者的空腹血糖以及甘油三酯和低密度脂蛋白含量均没有明显改善效果,而实施例3的液体饮料在2周时即可显著降低糖尿病患者的空腹血糖以及甘油三酯和低密度脂蛋白含量。
表3.饮用本饮料对糖尿病的改善
附图1显示,肠道菌群的多样性指数chao1(图1)和PD whole tree指数(图2)大幅提高,3种饮料均有一定提升幅度,但实施例3的饮料促进作用最为显著,在菌属水平上,实施例3的饮料会使糖尿病患者的有益菌Bifidobacterium(图3)和Akkermansia(图4)显著增加,促炎细菌Desulfovibrio(图4)和Clostridium(图5)大幅降低,对比例1和对比例2的饮料虽然也不同程度上改善了细菌组成的异常,但效果明显不如实施例3的饮料效果好,尤其是对于肠道的菌群多样性和有益菌Bifidobacterium的改善作用有显著差异。
以上说明本发明特定比例的各种原料,尤其是桑叶提取物、山楂提取物与壳寡糖之间具有协同作用,缺一不可,且比例必须恰当,当减少其中一个组分(如对比例1)或者改变其比例(如对比例2)时,就会显著减缓对糖尿病患者各项指标的改善作用,大大降低其对糖尿病患者的保健功效。只有在本发明范围内的各原料相互配合才能快速并显著地降低病人的甘油三酯及低密度脂蛋白含量,提高高密度脂蛋白水平,有效逆转高血脂症状,并且显著提升肠道菌群的多样性指数和有益菌相对数量,同时大幅降低促炎细菌等有害细菌。
以上显示和描述了本发明的基本原理、主要特征和优点,尽管已经示出和描述了本发明的实施例,对于本领域的普通技术人员而言,可以理解在不脱离本发明的原理和精神的情况下可以对这些实施例进行多种变化、修改、替换和变型,本发明的范围由所附权利要求及其等同物限定。
Claims (10)
1.一种含壳寡糖的液体健康饮料,其特征在于,由以下质量份数的原料和水混合配制而成:壳寡糖40-80份、山楂提取物20-50份、桑叶提取物8-20份、甜菊糖苷8-20份、柠檬酸5-20份、柠檬酸钠2-20份、食品添加剂0.01-0.1份;所述壳寡糖在液体健康饮料中的最终浓度为0.1-10mg/mL。
2.根据权利要求1所述的含壳寡糖的液体健康饮料,其特征在于,由以下质量份数的原料和水混合配制而成:壳寡糖50-70份、山楂提取物30-50份、桑叶提取物8-18份、甜菊糖苷8-16份、柠檬酸6-15份、柠檬酸钠3-10份、食品添加剂0.02-0.08份;所述壳寡糖在液体健康饮料中的最终浓度为0.2-5mg/mL。
3.根据权利要求1所述的含壳寡糖的液体健康饮料,其特征在于,所述山楂提取物的浓度为10%-30%,是山楂果经常规水提方法得到的组分。
4.根据权利要求1所述的含壳寡糖的液体健康饮料,其特征在于,所述桑叶提取物浓度为5%,是桑叶经常规水提方法得到的组分。
5.根据权利要求1所述的含壳寡糖的液体健康饮料,其特征在于,所述壳寡糖聚合度为2-20之间,分子量200-5000Da。
6.根据权利要求1到5任一项所述的含壳寡糖的液体健康饮料,其特征在于,所述食品添加剂包括益菌物质、防腐剂。
7.根据权利要求6所述的含壳寡糖的液体健康饮料,其特征在于,所述益菌物质为菊粉、魔芋粉、果寡糖、木寡糖、甘露寡糖中的至少一种。
8.根据权利要求6所述的含壳寡糖的液体健康饮料,其特征在于,所述防腐剂为苯甲酸钠、山梨酸钾、丙酸钠中的至少一种。
9.权利要求1到8任一项所述的含壳寡糖的液体健康饮料的制备方法,其特征在于,包括以下步骤:
(1)将壳寡糖、甜菊糖苷、柠檬酸、柠檬酸钠、食品添加剂等固体按比例加入水中,混匀;
(2)再将桑叶提取物和山楂提取物加入步骤(1)所得的混合物中,混匀;
(3)采用巴氏消毒法,将步骤(2)所得混合物在70℃条件下灭菌30min,然后按体积分装后迅速降低至4℃,并冷藏保存。
10.权利要求1到8任一项所述的含壳寡糖的液体健康饮料在调节肠道菌群紊乱或/和糖脂代谢紊乱疾病的保健食品和药物制剂中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811325019.8A CN109480132A (zh) | 2018-11-08 | 2018-11-08 | 一种含壳寡糖的液体健康饮料及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811325019.8A CN109480132A (zh) | 2018-11-08 | 2018-11-08 | 一种含壳寡糖的液体健康饮料及其制备方法和应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN109480132A true CN109480132A (zh) | 2019-03-19 |
Family
ID=65695388
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811325019.8A Pending CN109480132A (zh) | 2018-11-08 | 2018-11-08 | 一种含壳寡糖的液体健康饮料及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109480132A (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109924336A (zh) * | 2019-04-04 | 2019-06-25 | 维乐维健康产业有限公司 | 一种高吸收叶黄素酯玉米黄质软糖的制备方法 |
CN110664835A (zh) * | 2019-12-09 | 2020-01-10 | 中国科学院烟台海岸带研究所 | 含壳寡糖、菊糖、鞣花酸两种或以上的复合物及应用 |
CN115428851A (zh) * | 2022-09-02 | 2022-12-06 | 江西天帝仁医药科技有限公司 | 一种增强肠胃功能及免疫力几丁寡糖食品及其制备方法 |
CN117481345A (zh) * | 2024-01-03 | 2024-02-02 | 四川如源科技有限公司 | 一种具有肠胃调节功能的壳寡糖组合物及功能糖 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1883585A (zh) * | 2005-06-24 | 2006-12-27 | 江苏康缘药业股份有限公司 | 治疗动脉粥样硬化的药物组合物及其制备方法 |
CN1919027A (zh) * | 2006-08-25 | 2007-02-28 | 华雪芳 | 保健饮用茶及制备方法 |
CN102356911A (zh) * | 2011-11-01 | 2012-02-22 | 扬州大学 | 一种具有降血糖功效的桑叶汁饮料及其制备 |
CN105533387A (zh) * | 2015-12-09 | 2016-05-04 | 山东凯尔海洋生物科技有限公司 | 一种含有菊粉和壳寡糖的固体饮料及其制备方法 |
CN105595308A (zh) * | 2015-11-27 | 2016-05-25 | 青岛银色世纪健康产业集团有限公司 | 一种具有辅助降血糖功能的壳寡糖复合粉及其制备方法 |
CN105616958A (zh) * | 2015-12-25 | 2016-06-01 | 浙江华方生命科技有限公司 | 降血糖组合物、降血糖保健食品及其制备方法和应用 |
CN108157971A (zh) * | 2018-02-08 | 2018-06-15 | 沈勇子 | 一种壳寡糖液体口服制剂及其制备方法 |
CN108514563A (zh) * | 2018-02-28 | 2018-09-11 | 中国科学院过程工程研究所 | 壳寡糖、含有壳寡糖的组合物、含有壳寡糖的药物或食品及壳寡糖的应用 |
-
2018
- 2018-11-08 CN CN201811325019.8A patent/CN109480132A/zh active Pending
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1883585A (zh) * | 2005-06-24 | 2006-12-27 | 江苏康缘药业股份有限公司 | 治疗动脉粥样硬化的药物组合物及其制备方法 |
CN1919027A (zh) * | 2006-08-25 | 2007-02-28 | 华雪芳 | 保健饮用茶及制备方法 |
CN102356911A (zh) * | 2011-11-01 | 2012-02-22 | 扬州大学 | 一种具有降血糖功效的桑叶汁饮料及其制备 |
CN105595308A (zh) * | 2015-11-27 | 2016-05-25 | 青岛银色世纪健康产业集团有限公司 | 一种具有辅助降血糖功能的壳寡糖复合粉及其制备方法 |
CN105533387A (zh) * | 2015-12-09 | 2016-05-04 | 山东凯尔海洋生物科技有限公司 | 一种含有菊粉和壳寡糖的固体饮料及其制备方法 |
CN105616958A (zh) * | 2015-12-25 | 2016-06-01 | 浙江华方生命科技有限公司 | 降血糖组合物、降血糖保健食品及其制备方法和应用 |
CN108157971A (zh) * | 2018-02-08 | 2018-06-15 | 沈勇子 | 一种壳寡糖液体口服制剂及其制备方法 |
CN108514563A (zh) * | 2018-02-28 | 2018-09-11 | 中国科学院过程工程研究所 | 壳寡糖、含有壳寡糖的组合物、含有壳寡糖的药物或食品及壳寡糖的应用 |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109924336A (zh) * | 2019-04-04 | 2019-06-25 | 维乐维健康产业有限公司 | 一种高吸收叶黄素酯玉米黄质软糖的制备方法 |
CN110664835A (zh) * | 2019-12-09 | 2020-01-10 | 中国科学院烟台海岸带研究所 | 含壳寡糖、菊糖、鞣花酸两种或以上的复合物及应用 |
CN115428851A (zh) * | 2022-09-02 | 2022-12-06 | 江西天帝仁医药科技有限公司 | 一种增强肠胃功能及免疫力几丁寡糖食品及其制备方法 |
CN117481345A (zh) * | 2024-01-03 | 2024-02-02 | 四川如源科技有限公司 | 一种具有肠胃调节功能的壳寡糖组合物及功能糖 |
CN117481345B (zh) * | 2024-01-03 | 2024-04-05 | 四川如源科技有限公司 | 一种具有肠胃调节功能的壳寡糖组合物及功能糖 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109480132A (zh) | 一种含壳寡糖的液体健康饮料及其制备方法和应用 | |
CN102657262B (zh) | 聚葡萄糖在配方奶喂养的婴儿体内模拟人乳低聚糖的功能属性的用途 | |
TWI391138B (zh) | 含有纖維寡糖之組合物 | |
CN105192832A (zh) | 一种益生菌发酵辣木叶的组合物及其制备方法和应用 | |
JP5498698B2 (ja) | シロキクラゲ雑多糖またはその抽出物の新用途 | |
Ahmad et al. | Prebiotics and iron bioavailability? Unveiling the hidden association-A review | |
WO2011160420A1 (zh) | 绿牛奶 | |
CN1913911A (zh) | 功能性饮料及组合物 | |
CN101185511A (zh) | 具有肠胃微生态调节作用的保健方便面食品的制作方法 | |
CN105123929B (zh) | 一种降低胆固醇的褐藻寡糖乳制品 | |
JP2816726B2 (ja) | 腸内環境改善用組成物 | |
CN104780784A (zh) | 包含干混纯谷物β-葡聚糖和抗性淀粉的粉状营养组合物 | |
Jackson et al. | Food for thought! Inulin-type fructans: Does the food matrix matter? | |
CN114128813A (zh) | 一种用于解酒护肝后生元饮品及其制备方法 | |
Basharat et al. | Nutritional and functional profile of carob bean (Ceratonia siliqua): A comprehensive review | |
CN111066991A (zh) | 一种改善胃肠道功能的复合益生元固体饮料的制备方法 | |
CN107307258A (zh) | 一种益生菌纤维粉固体饮料 | |
CN104738773A (zh) | 一种植物饮料及制备工艺 | |
CN112931883A (zh) | 一种益生元组合物及其制备方法和应用 | |
CN101297820A (zh) | 屎链球菌功能信号分子制剂及其降脂减肥制品 | |
KR101421284B1 (ko) | 변비 개선용 조성물 및 이의 제조방법 | |
CN108201122A (zh) | 具有改善肠道菌群结构作用的蛹虫草组合物及制备方法 | |
CN103920140A (zh) | 一种人用降糖减肥降脂复方制剂 | |
KR101952991B1 (ko) | 맥주 생산으로부터 생성되는 바이오매스로부터 얻은 지방 결합제 | |
CN101380102A (zh) | 富硒松花粉健康食品及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190319 |
|
RJ01 | Rejection of invention patent application after publication |